VYD222 (pemivibart) — Competitive Intelligence Brief

VYD222 (pemivibart) (VYD222 (pemivibart)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiviral. Area: Infectious Disease.

phase 3 Antiviral SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) Infectious Disease Small molecule

Target snapshot

VYD222 (pemivibart) (VYD222 (pemivibart)) — Invivyd, Inc.. VYD222 (pemivibart) is an investigational antiviral medication that works by inhibiting the replication of SARS-CoV-2.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
VYD222 (pemivibart) TARGET	VYD222 (pemivibart)	Invivyd, Inc.	phase 3	Antiviral	SARS-CoV-2 RNA-dependent RNA polymerase (RdRp)
Paxlovid (Copackaged)	Nirmatrelvir	Pfizer	marketed	Antiviral protease inhibitor	SARS-CoV-2 main protease (Mpro, 3CLpro, nsp5 protease)	2023-01-01
Lonsurf	TIPIRACIL	Taiho Oncology Inc	marketed	Nucleoside Analog Antiviral [EPC]	Thymidine phosphorylase	2015-01-01
PODOFILOX	PODOFILOX		marketed	Topical antiviral	Unknown	1990-01-01
Dendrid	IDOXURIDINE	Novartis	marketed	Nucleoside Analog Antiviral	Thymidine kinase, cytosolic	1963-01-01
Ribavirin, Peg interferon alfa 2b	Ribavirin, Peg interferon alfa 2b	Brooke Army Medical Center	marketed	Antiviral combination therapy	HCV RNA-dependent RNA polymerase; interferon-alpha receptor
Combined therapy LDV and SOF	Combined therapy LDV and SOF	Yassin Abdelghaffar Charity Center for Liver Disease and Research	marketed	Direct-acting antiviral combination (NS5A inhibitor + nucleotide polymerase inhibitor)	HCV NS5A protein and HCV NS5B RNA-dependent RNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2029-09-22 — Lonsurf · RE46284 · US
• 2034-06-17 — Lonsurf · 10457666 · US
• 2034-06-17 — Lonsurf · 9527833 · US
• 2034-09-05 — Lonsurf · 9943537 · US
• 2037-02-03 — Lonsurf · 10456399 · US
• 2037-02-03 — Lonsurf · 10960004 · US
• 2041-08-05 — Paxlovid (Copackaged) · 11351149 · US
• 2041-10-31 — Paxlovid (Copackaged) · 11541034 · US

Sponsor landscape (Antiviral class)

1. Ain Shams University · 1 drug in this class
2. Arbutus Biopharma Corporation · 1 drug in this class
3. Australasian Gastro-Intestinal Trials Group · 1 drug in this class
4. Casa Sollievo della Sofferenza IRCCS · 1 drug in this class
5. Hospital Universitari Vall d'Hebron Research Institute · 1 drug in this class
6. Invivyd, Inc. · 1 drug in this class
7. JW Pharmaceutical · 1 drug in this class
8. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 1 drug in this class
9. Pfizer · 1 drug in this class
10. Professor Francois Venter · 1 drug in this class